305 related articles for article (PubMed ID: 24796150)
1. [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Ueno H; Nakazato M
Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):753-9. PubMed ID: 24796150
[No Abstract] [Full Text] [Related]
2. Recent advancements in drug treatment of obesity.
Carter R; Mouralidarane A; Ray S; Soeda J; Oben J
Clin Med (Lond); 2012 Oct; 12(5):456-60. PubMed ID: 23101148
[TBL] [Abstract][Full Text] [Related]
3. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
4. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety of the new anti-obesity medications.
Hainer V; Aldhoon-Hainerová I
Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
[TBL] [Abstract][Full Text] [Related]
7. Obesity Pharmacotherapy.
Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
9. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
Rubio MA
Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595
[No Abstract] [Full Text] [Related]
11. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Fujioka K; Braverman-Panza J
J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
[TBL] [Abstract][Full Text] [Related]
12. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Bays HE; Gadde KM
Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy for obesity: What you need to know.
Bersoux S; Byun TH; Chaliki SS; Poole KG
Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650
[TBL] [Abstract][Full Text] [Related]
14. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B; Mancini MC
Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
[TBL] [Abstract][Full Text] [Related]
15. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
16. Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.
Prescrire Int; 2013 Mar; 22(136):61-4. PubMed ID: 23593686
[TBL] [Abstract][Full Text] [Related]
17. [The pharmacotherapy of obesity].
Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G
Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782
[TBL] [Abstract][Full Text] [Related]
18. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
Cunningham JW; Wiviott SD
Clin Cardiol; 2014 Nov; 37(11):693-9. PubMed ID: 25223901
[TBL] [Abstract][Full Text] [Related]
19. Phentermine and topiramate extended release (Qsymia™): first global approval.
Cameron F; Whiteside G; McKeage K
Drugs; 2012 Oct; 72(15):2033-42. PubMed ID: 23039320
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]